Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty

Song, Tao; Song, Min; Ge, Zhiming; Li, Yong; Shi, Peimiao; Sun, Menghan

doi:10.1111/joic.12381

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most study reports evaluating the incidence of CI-AKI focused on low-osmolar contrast agents [11,33]. Recent data support the use of iso-osmolar contrast media to prevent CI-AKI both for intravenous and intraarterial administration, particularly in the setting of CKD [34][35][36][37]. In a randomized clinical trial performed in cancer patients, Terrenato et al reported a more favorable safety profile of Iodixanol vs. Iopromide [37].…”

Section: Discussionmentioning

confidence: 99%

Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol

et al. 2020

View full text Add to dashboard Cite

Objectives To determine the incidence of post-contrast acute kidney injury (PC-AKI) and presumed contrast-induced acute kidney injury (CI-AKI) following contrast-enhanced CT (CECT) with intravenous application of a reduced dose of the iso-osmolar contrast agent iodixanol in cancer patients with chronic kidney disease. Methods 198 oncology patients with a baseline estimated glomerular filtration rate (eGFR) <60ml/ min/1.73m 2 undergoing a total of 237 CECTs using a reduced dose of 60ml iodixanol were retrospectively analyzed. Statistical analysis was performed for the entire cohort and subgroups. The effect of additional risk factors on the occurrence of PC-AKI was evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nie et al (2008) compared the incidence of CI-AKI in patients with CKD, who underwent coronarography with or without percutaneous revascularization, randomized to iodixanol vs iopromide, experiencing an incidence of CI-AKI significantly lower in the IOCM group compared with the LOCM patients (5.7 vs 16.7%; P = 0.011). Song et al (2017) randomized 220 patients with heart failure and reduced left ventricular systolic function (with or without PCI) to iodixanol or iohexol. The primary endpoint was the incidence of CI-AKI 72h after the coronary procedure.…”

Section: Contrast Media Osmolality To Reduce the Risk Of Contrast-indmentioning

confidence: 99%

Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians

Ronco

Tarantini²,

McCullough

2020

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Contrast-induced acute kidney injury (CI-AKI) is a serious complication that can affect outcome and prognosis of patients undergoing percutaneous diagnostic and interventional procedures in catheterization laboratories. There have been advancements in case definition and epidemiology. Additionally strategies have emerged that are positioned to have impact in the catheterization laboratory for patients undergoing cardiovascular procedures. The aim of this review is to provide the state-of-the-art of diagnosis, prevention and management of CI-AKI in interventional cardiology.

show abstract

“…The side effects induced by ICAs are partially attributed to their hypertonic or hypotonic properties. Although the third generation ICAs, namely nonionic dimer such as iodixanol, possesses iso-osmolality and are believed to induce lower incidence of side effects [6], they still may lead to nephropathy and adverse cardiac events [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Bismuth chelate as a contrast agent for X-ray computed tomography

Guo

Qin

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

Backgrounds: Due to the unexpected side effects of the iodinated contrast agents, novel contrast agents for X-ray computed tomography (CT) imaging are urgently needed. Nanoparticles made by heavy metal elements are often employed, such as gold and bismuth. These nanoparticles have the advantages of long in vivo circulation time and tumor targeted ability. However, due to the long residence time in vivo, these nanoparticles may bring unexpected toxicity and, the preparation methods of these nanoparticles are complicated and time-consuming. Methods: In this investigation, a small molecular bismuth chelate using diethylenetriaminepentaacetic acid (DPTA) as the chelating agent was proposed to be an ideal CT contrast agent. Results: The preparation method is easy and cost-effective. Moreover, the bismuth agent show better CT imaging for kidney than iohexol in the aspect of improved CT values. Up to 500 µM, the bismuth agent show negligible toxicity to L02 cells and negligible hemolysis. And, the bismuth agent did not induce detectable morphology changes to the main organs of the mice after intravenously repeated administration at a high dose of 250 mg/kg. The pharmacokinetics of the bismuth agent follows the first-order elimination kinetics and, it has a short half-life time of 0.602 h. The rapid clearance from the body promised its excellent biocompatibility. Conclusions: This bismuth agent may serve as a potential candidate for developing novel contrast agent for CT imaging in clinical applications.

show abstract

Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty

Cited by 7 publications

References 25 publications

Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol

Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol

Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians

Bismuth chelate as a contrast agent for X-ray computed tomography

Contact Info

Product

Resources

About